Targeting chemokines: Pathogens can, why can't we?

Cytokine

Volumn 74, Issue 2, 2015, Pages 259-267

  Proudfoot, Amanda E I ^a   Bonvin, Pauline ^a   Power, Christine A ^b  

^a NOVIMMUNE SA   (Switzerland)

^b MERCK SERONO S A   (Switzerland)

Author keywords

Chemokine; Chemokine binding proteins; Glycosaminoglycan; Pathogens; Receptor inhibitors

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ABN 912; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; EVASIN; FOLLITROPIN; GONADOTROPIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; MC 148; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PLERIXAFOR; RANTES; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR STIMULATED GENE 6 PROTEIN; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; DISEASE COURSE; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; MOLLUSCUM CONTAGIOSUM VIRUS; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG DESIGN; IMMUNOLOGY;

ANIMALS; CHEMOKINES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; RECEPTORS, CHEMOKINE;

EID: 84949723522     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.011     Document Type: Article

References (112)

1. Nourshargh S., Alon R. Leukocyte migration into inflamed tissues. Immunity 2014, 41:694-707.
2. Couchman J.R., Pataki C.A. An introduction to proteoglycans and their localization. J Histochem Cytochem 2012, 60:885-897.
3. Pomin V.H. Sulfated glycans in inflammation. Eur J Med Chem 2015, 92C:353-369.
4. Hoogewerf A.J., Kuschert G.S., Proudfoot A.E., Borlat F., Clark-Lewis I., Power C.A., et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997, 36:13570-13578.
5. Rot A. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol 1993, 23:303-306.
6. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003, 100:1885-1890.
7. Lundstrom K. An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs. Methods Mol Biol 2009, 552:51-66.
8. Bachelerie F., Ben-Baruch A., Burkhardt A.M., Combadiere C., Farber J.M., Graham G.J., et al. International union of pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2014, 66:1-79.
9. Schall T.J., Proudfoot A.E. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011, 11:355-363.
10. Mack M., Luckow B., Nelson P.J., Cihak J., Simmons G., Clapham P.R., et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998, 187:1215-1224.
11. Zimmermann N., Conkright J.J., Rothenberg M.E. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J Biol Chem 1999, 274:12611-12618.
12. Elsner J., Mack M., Bruhl H., Dulkys Y., Kimmig D., Simmons G., et al. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 2000, 275:7787-7794.
13. Bardi G., Lipp M., Baggiolini M., Loetscher P. The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur J Immunol 2001, 31:3291-3297.
14. Ajram L., Begg M., Slack R., Cryan J., Hall D., Hodgson S., et al. Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists. Eur J Pharmacol 2014, 729:75-85.
15. Zohar Y., Wildbaum G., Novak R., Salzman A.L., Thelen M., Alon R., et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest 2014, 124:2009-2022.
16. Siciliano S.J., Rollins T.E., DeMartino J., Konteatis Z., Malkowitz L., Van R.G., et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994, 91:1214-1218.
17. Clark-Lewis I., Schumacher C., Baggiolini M., Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem 1991, 266:23128-23134.
18. Gong J.H., Uguccioni M., Dewald B., Baggiolini M., Clark-Lewis I. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 1996, 271:10521-10527.
19. Zhang Y., Rollins B.J. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 1995, 15:4851-4855.
20. Mortier A., Van D.J., Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther 2008, 120:197-217.
21. Gong J.H., Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 1995, 181:631-640.
22. Goser S., Ottl R., Brodner A., Dengler T.J., Torzewski J., Egashira K., et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 2005, 112:3400-3407.
23. Koga M., Kai H., Egami K., Murohara T., Ikeda A., Yasuoka S., et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008, 365:279-284.
24. Severin I.C., Souza A.L., Davis J.H., Musolino N., Mack M., Power C.A., et al. Properties of 7ND-CCL2 are modulated upon fusion to Fc. Protein Eng Des Sel 2012, 25:213-222.
25. Park I.K., Hiraki K., Kohyama K., Matsumoto Y. Differential effects of decoy chemokine (7ND) gene therapy on acute, biphasic and chronic autoimmune encephalomyelitis: implication for pathomechanisms of lesion formation. J Neuroimmunol 2008, 194:34-43.
26. Proudfoot A.E., Power C.A., Hoogewerf A.J., Montjovent M.O., Borlat F., Offord R.E., et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996, 271:2599-2603.
27. Plater-Zyberk C., Hoogewerf A.J., Proudfoot A.E., Power C.A., Wells T.N. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997, 57:117-120.
28. Grone H.J., Weber C., Weber K.S., Grone E.F., Rabelink T., Klier C.M., et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999, 13:1371-1383.
29. Ajuebor M.N., Hogaboam C.M., Kunkel S.L., Proudfoot A.E., Wallace J.L. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 2001, 166:552-558.
30. Chvatchko Y., Proudfoot A.E., Buser R., Juillard P., Alouani S., Kosco-Vilbois M., et al. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol 2003, 171:5498-5506.
31. Robinson S.C., Scott K.A., Wilson J.L., Thompson R.G., Proudfoot A.E., Balkwill F.R. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003, 63:8360-8365.
32. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276:276-279.
33. Shaw J.P., Johnson Z., Borlat F., Zwahlen C., Kungl A., Roulin K., et al. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure 2004, 12:2081-2093.
34. Scholten D.J., Canals M., Maussang D., Roumen L., Smit M.J., Wijtmans M., et al. Pharmacological modulation of chemokine receptor function. Br J Pharmacol 2012, 165:1617-1643.
35. Horuk R., Proudfoot A.E. Drug discovery targeting the chemokine system-where are we?. Front Biosci (Elite Ed) 2009, 1:209-219.
36. Solari R., Pease J.E., Begg M. Chemokine receptors as therapeutic targets: why aren't there more drugs?. Eur J Pharmacol 2015, 746:363-367.
37. Nichols W.G., Steel H.M., Bonny T., Adkison K., Curtis L., Millard J., et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008, 52:858-865.
38. Severin I.C., Soares A., Hantson J., Teixeira M., Sachs D., Valognes D., et al. Glycosaminoglycan analogs as a novel anti-inflammatory strategy. Front Immunol 2012, 3:293.
39. Nonaka M., Bao X., Matsumura F., Gotze S., Kandasamy J., Kononov A., et al. Synthetic di-sulfated iduronic acid attenuates asthmatic response by blocking T-cell recruitment to inflammatory sites. Proc Natl Acad Sci USA 2014, 111:8173-8178.
40. Vela M., Aris M., Llorente M., Garcia-Sanz J.A., Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol 2015.
41. Byrne H., Conroy P.J., Whisstock J.C., O'Kennedy R.J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013, 31:621-632.
42. Robak T., Windyga J., Trelinski J., von Depka P.M., Giagounidis A., Doyen C., et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012, 120:3670-3676.
43. Klarenbeek A., Maussang D., Blanchetot C., Saunders M., van der Woning S., Smit M., et al. Targeting chemokines and chemokine receptors with antibodies. Drug Discov Today Technol 2012, 9:e227-e314.
44. Haringman J.J., Gerlag D.M., Smeets T.J., Baeten D., van den Bosch F., Bresnihan B., et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2387-2392.
45. Chakraborty A., Van L.M., Skerjanec A., Floch D., Klein U.R., Krammer G., et al. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol 2013, 53:1240-1251.
46. Moore P.S., Boshoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274:1739-1744.
47. Parcells M.S., Lin S.F., Dienglewicz R.L., Majerciak V., Robinson D.R., Chen H.C., et al. Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV. J Virol 2001, 75:5159-5173.
48. Dairaghi D.J., Fan R.A., McMaster B.E., Hanley M.R., Schall T.J. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem 1999, 274:21569-21574.
49. Endres M.J., Garlisi C.G., Xiao H., Shan L., Hedrick J.A. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. J Exp Med 1999, 189:1993-1998.
50. Nakano K., Isegawa Y., Zou P., Tadagaki K., Inagi R., Yamanishi K. Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded vMIP-I and vMIP-II induce signal transduction and chemotaxis in monocytic cells. Arch Virol 2003, 148:871-890.
51. Engel A.T., Selvaraj R.K., Kamil J.P., Osterrieder N., Kaufer B.B. Marek's disease viral interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and CD4+ CD25+ T cells. J Virol 2012, 86:8536-8545.
52. Dewin D.R., Catusse J., Gompels U.A. Identification and characterization of U83A viral chemokine, a broad and potent beta-chemokine agonist for human CCRs with unique selectivity and inhibition by spliced isoform. J Immunol 2006, 176:544-556.
53. Luttichau H.R. The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist. J Biol Chem 2010, 285:9137-9146.
54. Stine J.T., Wood C., Hill M., Epp A., Raport C.J., Schweickart V.L., et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000, 95:1151-1157.
55. de P.A., De P.R., Di G.L., Carfora M., Prevete N., Tosi G., et al. Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI+ cells. J Immunol 2000, 165:7171-7179.
56. Penfold M., Miao Z., Wang Y., Haggerty S., Schleiss M.R. A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1. Virology 2003, 316:202-212.
57. Saederup N., Lin Y.C., Dairaghi D.J., Schall T.J., Mocarski E.S. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proc Natl Acad Sci USA 1999, 96:10881-10886.
58. Vomaske J., Denton M., Kreklywich C., Andoh T., Osborn J.M., Chen D., et al. Cytomegalovirus CC chemokine promotes immune cell migration. J Virol 2012, 86:11833-11844.
59. Damon I., Murphy P.M., Moss B. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc Natl Acad Sci USA 1998, 95:6403-6407.
60. Krathwohl M.D., Hromas R., Brown D.R., Broxmeyer H.E., Fife K.H. Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc Natl Acad Sci USA 1997, 94:9875-9880.
61. Jin Q., Altenburg J.D., Hossain M.M., Alkhatib G. Role for the conserved N-terminal cysteines in the anti-chemokine activities by the chemokine-like protein MC148R1 encoded by Molluscum contagiosum virus. Virology 2011, 417:449-456.
62. Luttichau H.R., Stine J., Boesen T.P., Johnsen A.H., Chantry D., Gerstoft J., et al. A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. J Exp Med 2000, 191:171-180.
63. Kledal T.N., Rosenkilde M.M., Coulin F., Simmons G., Johnsen A.H., Alouani S., et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997, 277:1656-1659.
64. Chen S., Bacon K.B., Li L., Garcia G.E., Xia Y., Lo D., et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998, 188:193-198.
65. Shan L., Qiao X., Oldham E., Catron D., Kaminski H., Lundell D., et al. Identification of viral macrophage inflammatory protein (vMIP)-II as a ligand for GPR5/XCR1. Biochem Biophys Res Commun 2000, 268:938-941.
66. Luttichau H.R., Lewis I.C., Gerstoft J., Schwartz T.W. The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor. Eur J Immunol 2001, 31:1217-1220.
67. Luttichau H.R. The herpesvirus 8 encoded chemokines vCCL2 (vMIP-II) and vCCL3 (vMIP-III) target the human but not the murine lymphotactin receptor. Virol J 2008, 5:50.
68. Yamin R., Kaynan N.S., Glasner A., Vitenshtein A., Tsukerman P., Bauman Y., et al. The viral KSHV chemokine vMIP-II inhibits the migration of Naive and activated human NK cells by antagonizing two distinct chemokine receptors. PLoS Pathog 2013, 9:e1003568.
69. Rubant S., Ludwig R.J., Pfeffer J., Schulze-Johann P., Kaufmann R., Pfeilschifter J.M., et al. Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo. Exp Dermatol 2006, 15:634-642.
70. Weber K.S., Grone H.J., Rocken M., Klier C., Gu S., Wank R., et al. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol 2001, 31:2458-2466.
71. Zhao B., Liwang P.J. Characterization of the interactions of vMIP-II, and a dimeric variant of vMIP-II, with glycosaminoglycans. Biochemistry 2010, 49:7012-7022.
72. Qin L., Kufareva I., Holden L.G., Wang C., Zheng Y., Zhao C., et al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 2015.
73. Smith P., Fallon R.E., Mangan N.E., Walsh C.M., Saraiva M., Sayers J.R., et al. Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. J Exp Med 2005, 202:1319-1325.
74. Dyer D.P., Thomson J.M., Hermant A., Jowitt T.A., Handel T.M., Proudfoot A.E., et al. TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J Immunol 2014, 192:2177-2185.
75. Burns J.M., Dairaghi D.J., Deitz M., Tsang M., Schall T.J. Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J Biol Chem 2002, 277:2785-2789.
76. Kuo N.W., Gao Y.G., Schill M.S., Isern N., Dupureur C.M., Liwang P.J. Structural insights into the interaction between a potent anti-inflammatory protein, viral CC chemokine inhibitor (vCCI), and the human CC chemokine, Eotaxin-1. J Biol Chem 2014, 289:6592-6603.
77. White G.E., McNeill E., Christou I., Channon K.M., Greaves D.R. Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade. Mol Pharmacol 2011, 80:328-336.
78. Zhang L., Derider M., McCornack M.A., Jao S.C., Isern N., Ness T., et al. Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta. Proc Natl Acad Sci USA 2006, 103:13985-13990.
79. Alcami A., Symons J.A., Collins P.D., Williams T.J., Smith G.L. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998, 160:624-633.
80. Smith C.A., Smith T.D., Smolak P.J., Friend D., Hagen H., Gerhart M., et al. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 1997, 236:316-327.
81. Buatois V., Fagete S., Magistrelli G., Chatel L., Fischer N., Kosco-Vilbois M.H., et al. Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis. J Immunol 2010, 185:2544-2554.
82. Dabbagh K., Xiao Y., Smith C., Stepick-Biek P., Kim S.G., Lamm W.J., et al. Local blockade of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI. J Immunol 2000, 165:3418-3422.
83. Lalani A.S., Graham K., Mossman K., Rajarathnam K., Clark-Lewis I., Kelvin D., et al. The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J Virol 1997, 71:4356-4363.
84. Liu L., Lalani A., Dai E., Seet B., Macauley C., Singh R., et al. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J Clin Invest 2000, 105:1613-1621.
85. Parry C.M., Simas J.P., Smith V.P., Stewart C.A., Minson A.C., Efstathiou S., et al. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J Exp Med 2000, 191:573-578.
86. van Berkel V., Barrett J., Tiffany H.L., Fremont D.H., Murphy P.M., et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000, 74:6741-6747.
87. Jensen K.K., Chen S.C., Hipkin R.W., Wiekowski M.T., Schwarz M.A., Chou C.C., et al. Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J Virol 2003, 77:624-630.
88. Martin A.P., Canasto-Chibuque C., Shang L., Rollins B.J., Lira S.A. The chemokine decoy receptor M3 blocks CC chemokine ligand 2 and CXC chemokine ligand 13 function in vivo. J Immunol 2006, 177:7296-7302.
89. Webb L.M., Smith V.P., Alcami A. The gammaherpesvirus chemokine binding protein can inhibit the interaction of chemokines with glycosaminoglycans. FASEB J 2004, 18:571-573.
90. Webb L.M., Clark-Lewis I., Alcami A. The gammaherpesvirus chemokine binding protein binds to the N terminus of CXCL8. J Virol 2003, 77:8588-8592.
91. Alexander J.M., Nelson C.A., van Berkel V., Lau E.K., Studts J.M., et al. Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 2002, 111:343-356.
92. Alexander-Brett J.M., Fremont D.H. Dual GPCR and GAG mimicry by the M3 chemokine decoy receptor. J Exp Med 2007, 204:3157-3172.
93. Ausubel L.J., Meseck M., Derecho I., Lopez P., Knoblauch C., McMahon R., et al. Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. Hum Gene Ther 2011, 22:489-497.
94. Bahar M.W., Kenyon J.C., Putz M.M., Abrescia N.G., Pease J.E., Wise E.L., et al. Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 2008, 4:e5.
95. Ruiz-Arguello M.B., Smith V.P., Campanella G.S., Baleux F., Arenzana-Seisdedos F., Luster A.D., et al. An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain. J Virol 2008, 82:917-926.
96. Mahoney D.J., Mulloy B., Forster M.J., Blundell C.D., Fries E., Milner C.M., et al. Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin: implications for the inhibition of plasmin in extracellular matrix microenvironments. J Biol Chem 2005, 280:27044-27055.
97. Parkar A.A., Day A.J. Overlapping sites on the Link module of human TSG-6 mediate binding to hyaluronan and chrondroitin-4-sulphate. FEBS Lett 1997, 410:413-417.
98. Lubman O.Y., Cella M., Wang X., Monte K., Lenschow D.J., Huang Y.H., et al. Rodent herpesvirus Peru encodes a secreted chemokine decoy receptor. J Virol 2014, 88:538-546.
99. Seet B.T., Barrett J., Robichaud J., Shilton B., Singh R., McFadden G. Glycosaminoglycan binding properties of the myxoma virus CC-chemokine inhibitor, M-T1. J Biol Chem 2001, 276:30504-30513.
100. Frauenschuh A., Power C.A., Deruaz M., Ferreira B.R., Silva J.S., Teixeira M.M., et al. Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus. J Biol Chem 2007, 282:27250-27258.
101. Deruaz M., Frauenschuh A., Alessandri A.L., Dias J.M., Coelho F.M., Russo R.C., et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008, 205:2019-2031.
102. Deruaz M., Bonvin P., Severin I.C., Johnson Z., Krohn S., Power C.A., et al. Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models. FEBS J 2013, 280:4876-4887.
103. Dias J.M., Losberger C., Deruaz M., Power C.A., Proudfoot A.E., Shaw J.P. Structural basis of chemokine sequestration by a tick chemokine binding protein: the crystal structure of the complex between Evasin-1 and CCL3. PLoS ONE 2009, 4:e8514.
104. Bonvin P., Dunn S.M., Rousseau F., Dyer D.P., Shaw J., Power C.A., et al. Identification of the pharmacophore of the CC chemokine-binding proteins Evasin-1 and -4 using phage display. J Biol Chem 2014, 289:31846-31855.
105. Montecucco F., Lenglet S., Braunersreuther V., Pelli G., Pellieux C., Montessuit C., et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010, 30:1371-1377.
106. Russo R.C., Alessandri A.L., Garcia C.C., Cordeiro B.F., Pinho V., Cassali G.D., et al. Therapeutic effects of Evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 45:72-80.
107. Vieira A.T., Fagundes C.T., Alessandri A.L., Castor M.G., Guabiraba R., Borges V.O., et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol 2009, 175:2382-2391.
108. Braunersreuther V., Montecucco F., Pelli G., Galan K., Proudfoot A.E., Belin A., et al. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb Haemost 2013, 110:807-825.
109. Castor M.G., Rezende B., Resende C.B., Alessandri A.L., Fagundes C.T., Sousa L.P., et al. The CCL3/macrophage inflammatory protein-1alpha-binding protein Evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol 2010, 184:2646-2654.
110. Montecucco F., Mach F., Lenglet S., Vonlaufen A., Gomes Quindere A.L., Pelli G., et al. Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis. Eur J Clin Invest 2014, 44:940-950.
111. Alejo A., Ruiz-Arguello M.B., Ho Y., Smith V.P., Saraiva M., Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci USA 2006, 103:5995-6000.
112. Antonets D.V., Nepomnyashchikh T.S., Shchelkunov S.N. SECRET domain of variola virus CrmB protein can be a member of poxviral type II chemokine-binding proteins family. BMC Res Notes 2010, 3:271.